PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
July 30 2020 - 04:05PM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology, today announced that the
Company will report financial results for the second quarter ended
June 30, 2020 on Thursday, August 13, 2020, before the market
opens. Following the release, Dr. Frank Bedu-Addo, Chief Executive
Officer, Michael King, Interim Chief Financial Officer, and Dr.
Lauren Wood, Chief Medical Officer will host a conference call to
review the financial results and provide a business update.
The conference call is scheduled to begin at
8:00 am ET on Thursday, August 13, 2020. Participants should dial
877-407-3088 (United States) or 201-389-0927 (International) and
mention PDS Biotechnology. A live webcast of the conference call
will also be available on the investor relations page of the
Company's corporate website at www.pdsbiotech.com.
After the live webcast, the event will be
archived on PDS Biotech’s website for 6 months. In addition, a
telephonic replay of the call will be available for 6 months. The
replay can be accessed by dialing 877-660-6853 (United States) or
201-612-7415 (International) with confirmation code 13707451.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy
company with a growing pipeline of cancer immunotherapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology platform. Versamune®
effectively delivers disease-specific antigens for in vivo uptake
and processing, while also activating the critical type 1
interferon immunological pathway, resulting in production of potent
disease-specific killer T-cells as well as neutralizing antibodies.
PDS Biotech has engineered multiple therapies, based on
combinations of Versamune® and disease-specific antigens, designed
to train the immune system to better recognize disease cells and
effectively attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Media & Investor Relations
Contact:
Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Alexander LoboThe Ruth GroupPhone: +1 (646)
536-7037Email: alobo@theruthgroup.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Feb 2024 to Mar 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2023 to Mar 2024